China smartphone shipments slumped in June on inventory overhang: Jefferies
In recent transactions reported by Liquidia Corp (NASDAQ:LQDA), a biopharmaceutical company with a market capitalization of $1.16 billion, Jason Adair, the company’s Chief Business Officer, executed a sale of 1,856 shares of common stock on April 14, 2025. The shares were sold at $13.57 each, totaling approximately $25,185. This transaction was conducted under a pre-established Rule 10b5-1 trading plan that Adair adopted in December 2023. InvestingPro analysis indicates the stock is trading above its Fair Value, with analysts setting price targets between $20 and $35.
Additionally, on April 11, 2025, Adair acquired 3,906 shares of common stock through the vesting of restricted stock units (RSUs). These RSUs were originally part of a grant given to Adair in January 2023, with a vesting schedule that began in January 2024. The acquisition of these shares was at no cost, as each RSU represents a right to receive one share of Liquidia’s common stock. For comprehensive insider trading analysis and additional financial metrics, consider accessing the detailed Pro Research Report available on InvestingPro.
Post these transactions, Adair’s direct ownership stands at 184,304 shares, which includes both vested and unvested RSUs as well as shares acquired through Liquidia’s Employee Stock Purchase Plan. The company maintains strong liquidity with a current ratio of 4.43, though it reported negative earnings of -$1.66 per share over the last twelve months.
In other recent news, Liquidia Corporation reported its financial results for the fourth quarter of 2024, revealing a net loss and revenue shortfall compared to analyst forecasts. The company posted a Q4 2024 earnings per share (EPS) of -$0.45, missing the forecast of -$0.3821, and revenue of $2.92 million, which was below the expected $4.54 million. Despite the earnings miss, Liquidia remains focused on its key product, Yutrepia, which is anticipated to launch in May 2025 following the expiration of Tyvaso DPI’s regulatory exclusivity. The U.S. Food and Drug Administration (FDA) has accepted Liquidia’s resubmission for Yutrepia, setting a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2025, for a final decision. Analysts have shown varied confidence in Liquidia’s prospects; Scotiabank (TSX:BNS) raised its price target to $34, while H.C. Wainwright and Raymond (NSE:RYMD) James maintained targets of $29 and $27, respectively. Liquidia has secured a $100 million financing agreement with HealthCare Royalty to support Yutrepia’s development and commercialization. Additionally, new data from the ASCENT trial demonstrated a significant improvement in the six-minute walk test, enhancing Yutrepia’s profile in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.